Evidence map›Paper›PMID 34200837›Full record

ArticleMicroorganisms2021

Combination of rRT-PCR and Anti-Nucleocapsid/Anti-Spike Antibodies to Characterize Specimens with Very Low Viral SARs-CoV-2 Load: A Real-Life Experience.

Zoe Florou, Meropi Zigra, Philippos Kartalidis, Katerina Tsilipounidaki, Georgia Papadamou, Aikaterini Belia, George C Fthenakis, Efthymia Petinaki

Open access · goldAbstract read
In one paragraph

Article in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Zoe FlorouDepartment of Microbiology, University Hospital, University of Thessaly, 41110 Larisa, Greece.
Meropi ZigraDepartment of Microbiology, University Hospital, University of Thessaly, 41110 Larisa, Greece.
Philippos KartalidisDepartment of Microbiology, University Hospital, University of Thessaly, 41110 Larisa, Greece.
Katerina TsilipounidakiDepartment of Microbiology, University Hospital, University of Thessaly, 41110 Larisa, Greece.ORCID 0000-0002-2819-2089
Georgia PapadamouDepartment of Emergency, University Hospital, University of Thessaly, 41110 Larisa, Greece.
Aikaterini BeliaDepartment of Emergnecy, Hospital of Karditsa, 43100 Karditsa, Greece.
George C FthenakisVeterinary Faculty, University of Thessaly, 43100 Karditsa, Greece.
Efthymia PetinakiDepartment of Microbiology, University Hospital, University of Thessaly, 41110 Larisa, Greece.
University of Thessaly · GRDevelopment Agency of Karditsa · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of the present study was to evaluate the true positivity among people, whose results of initial testing of nasopharyngeal swabs (NPS) showed a very low viral load of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Seventy-seven people detected with low viral loads of SARs-CoV-2 in nasopharyngeal samples (Ct ≥ 35) were enrolled in the study. For this purpose, a second NPS was collected for rRT-PCR (real-time reverse transcription polymerase chain reaction) combined with a pair of serum samples for detection of anti-nucleocapsid (anti-N) and anti-spike (anti-S) antibodies. In 8 people, subsequent examinations indicated an increase in viral loads, thereafter, followed by an increase of anti-N and anti-S antibodies, findings compatible with an early stage of COVID-19 infection. In 9 people, who already had increased anti-N antibodies, subsequent examination showed a decrease or absence of viral load and an increase in antibodies, indicative of a late stage of COVID-19 infection. In 60 people, subsequent examination showed absence of infection (as indicated by absence of viral load and antibodies). We propose that the combination of a second NPS and one serum-specimen, both taken three days after the first NPS, helps significantly to avoid false-positive results.

Indexed as

anti-nucleocapsid antibodiesanti-spike antibodiesCOVID-19diagnosisfalse positiveGreecelow viral loadN gene

Identifiers

PMID34200837
PMCPMC8230444
OpenAlexW3165990793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.